Meeting
2020 ASCO Virtual Scientific Program
First-in-human phase I/Ib multicenter, open-label dose escalation study to assess safety and tolerability of PMD-026 in patients with metastatic breast cancer with expansion in metastatic triple negative breast cancer.
Authors
Muralidhar Beeram
START, San Antonio, TX
Muralidhar Beeram , Judy Sing-Zan Wang , Lida A. Mina , Amita Patnaik , Mary Rose Pambid , Aarthi Jayanthan , My-my Huynh , Sandra Elaine Dunn , Gerrit Los , Andrew Dorr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Triple-Negative
Clinical Trial Registration Number
NCT04115306
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS1110)
DOI
10.1200/JCO.2020.38.15_suppl.TPS1110
Abstract #
TPS1110
Poster Bd #
195
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer.
First Author: Virginia F. Borges
Poster
2023 ASCO Annual Meeting
Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study.
First Author: Kathleen N. Moore
Poster
2021 ASCO Annual Meeting
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
First Author: Vivek Subbiah
Poster
2020 ASCO Virtual Scientific Program
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer.
First Author: Dongmei Ji